Latest filing published 19 Sept 2025 for Jacobio Pharmaceuticals Group Co., Ltd. - B, €960k. Read the official filing
Based on 26 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Wang Yinxiang on record concern Jacobio Pharmaceuticals Group Co., Ltd. - B. In total, 38 filings cover trades dated from 21 December 2020 to 18 September 2025.
Market trades split into 26 purchases (€21.0M) and 10 sales (€41.1M). The amount is not disclosed for 4 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2025, the count stands at 11 purchases and 2 sales.
A typical purchase (the median) is worth €40k. On 26 out of 26 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 26 purchases old enough to measure, the stock rose over the following 90 days in 27% of cases; the median change was -10.3%. These figures describe past trades and do not predict future prices.
On 19 September 2025 came the latest disclosure, an open-market sale for €960k in Jacobio Pharmaceuticals Group Co., Ltd. - B. The most recent open-market purchase was published on 5 September 2025, 411 days ago. Filings reach the HKEX feed a median of 3 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 38 declarations